ROLE OF INTERLEUKIN 10 GENETIC POLYMORPHISMS IN RECTAL CANCER PATIENTS
Jorge Luis de León Rendón*, Raquel Yazmin López Pérez, Juan A. Villanueva-Herrero, Noé Isaías Gracida Mancilla, Billy Jiménez Bobadilla
Coloproctology , Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico, CDMX, Mexico
Background. Chronic inflammation is a well-established risk factor for colorectal cancer. Interleukin10 (IL-10) is a cytokine whose main biological function is to limit inflammatory responses and is crucial to maintain immune homeostasis of the gastrointestinal tract. Some single nucleotide polymorphisms (SNPs) of IL-10 have been associated with cancer risk.
Purpose. The aim of our study was to evaluate the role of SNPs rs1800896, rs1800872 and rs1800871 of IL-10 in patients with rectal cancer.
Methods. A prospective study was conducted in which 53 patients with rectal cancer confirmed by histopathology (Table 1) and 52 healthy controls were included. Information was collected focused on the demographic, clinical, biochemical characteristics; CT, MRI and histopathological reports of each patient, by reviewing the clinical reports. SNPs of IL-10 were genotyped by RT-PCR.
Results. We identified that the AA genotype of SNP rs1800872 behaved as a protective factor for invasion of regional nodes, presence of distant metastasis and for the development of a late stage of the disease. The CC genotype of SNP rs1800871 was a protective factor for the presence of distant metastasis, whereas its CT heterozygous form was at risk for greater local infiltration. Genotypic GG frequency of SNP rs1800896 was a risk factor for non-response to neoadjuvant therapy, whereas the heterozygous AG genotype represented a protective factor for the non-response to neoadjuvant therapy. The allelic frequency A and the homozygous AA genotype of SNP rs1800872 were protective factors for non-response to therapy neoadjuvant while the allelic frequency C and the CC genotype of the same polymorphic site were found as risk for the no response to neoadjuvance. As for the SNP rs1800871, the allelic frequency C and the CC genotype were protective for the non-response to neoadjuvant, whereas the allelic frequency T and the genotypic frequency TT resulted in risk for nonresponse to neoadjuvant therapy. Of the patients included who underwent surgical procedures, we found a protective factor for post-surgical complications at the allelic frequency A and the AA genotype of the SNP rs1800872, while its allelic frequency C behaved as a risk for postoperative complications. SNP rs1800871 is also involved in post-surgical complications, with its allelic frequency C and its homozygous CC genotype were protective factors for the development of post-surgical complications; however, its allelic frequency T and homozygous TT genotype represented a risk factor for postoperative complications (Table 2).
Conclusions. Our study suggests that interleukin 10 genetic polymorphisms could impact in different aspects in evolution of rectal cancer. This is the first study worldwide that associate polymorphisms of IL-10 with the neoadjuvant response and post-surgical outcomes exclusively in rectal cancer patients.
Back to 2020 Abstracts